Efficacy and Safety of Osteoporosis Treatment

  • Michael R. McClung


For postmenopausal women with osteoporosis, pharmacological therapy compliments adequate nutrition, regular physical activity, and, when appropriate, strategies to prevent falls, alleviate pain, and optimize function. The objective of drug therapy is to reduce the incidence of serious fragility fractures that can impair function, degrade quality of life, and even increase the risk of death. Several drugs with different mechanisms of action are available for clinical use. This chapter will review the effectiveness, important safety issues, and practical considerations in choosing among the most important treatment options. Salmon calcitonin (limited evidence of efficacy and no longer available in Europe) and strontium ranelate (modest evidence of efficacy, significant restrictions on use in Europe, and never available in the United States) will not be discussed.


Osteoporosis Bisphosphonates Estrogen agonist/antagonist Denosumab Teriparatide Fracture risk Vertebral fracture Hip fracture 


  1. 1.
    Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet. 1996;348:1535–41.CrossRefGoogle Scholar
  2. 2.
    Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA. 1999;282:1344–52.CrossRefGoogle Scholar
  3. 3.
    McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med. 2001;344:333–40.CrossRefGoogle Scholar
  4. 4.
    Chesnut CH III, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004;19:1241–9.CrossRefGoogle Scholar
  5. 5.
    Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356:1809–22.CrossRefGoogle Scholar
  6. 6.
    Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361:756–65.CrossRefGoogle Scholar
  7. 7.
    Tsourdi E, Langdahl B, Cohen-Solal M, et al. Discontinuation of denosumab therapy for osteoporosis: a systematic review and position statement by ECTS. Bone. 2017;105:11–7.CrossRefGoogle Scholar
  8. 8.
    Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA. 1999;282:637–45.CrossRefGoogle Scholar
  9. 9.
    Silverman SL, Christiansen C, Genant HK, et al. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res. 2008;23:1923–34.CrossRefGoogle Scholar
  10. 10.
    Roelofs AJ, Thompson K, Gordon S, Rogers MJ. Molecular mechanisms of action of bisphosphonates: current status. Clin Cancer Res. 2006;12:6222s–30s.CrossRefGoogle Scholar
  11. 11.
    Bone HG, Hosking D, Devogelaer JP, et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med. 2004;350:1189–99.CrossRefGoogle Scholar
  12. 12.
    Mellström DD, Sörensen OH, Goemaere S, Roux C, Johnson TD, Chines AA. Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int. 2004;75:462–8.CrossRefGoogle Scholar
  13. 13.
    Black DM, Reid IR, Cauley JA, et al. The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res. 2015;30:934–44.CrossRefGoogle Scholar
  14. 14.
    Watts NB, Chines A, Olszynski WP, et al. Fracture risk remains reduced one year after discontinuation of risedronate. Osteoporos Int. 2008;19:365–72.CrossRefGoogle Scholar
  15. 15.
    Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA. 2006;296:2927–38.CrossRefGoogle Scholar
  16. 16.
    Black DM, Reid IR, Boonen S, et al. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res. 2012;27:243–54.CrossRefGoogle Scholar
  17. 17.
    McClung M, Harris ST, Miller PD, et al. Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. Am J Med. 2013;126:13–20.CrossRefGoogle Scholar
  18. 18.
    Whitaker M, Guo J, Kehoe T, Benson G. Bisphosphonates for osteoporosis–where do we go from here? N Engl J Med. 2012;366:2048–51.CrossRefGoogle Scholar
  19. 19.
    Rosen CJ, Brown S. Severe hypocalcemia after intravenous bisphosphonate therapy in occult vitamin D deficiency. N Engl J Med. 2003;348:1503–4.CrossRefGoogle Scholar
  20. 20.
    Fosamax Prescribing Information. Merck & Co, Inc; 2012.Google Scholar
  21. 21.
    Actonal Prescribing Information. Warner-Chilcott US, LLC; 2015.Google Scholar
  22. 22.
    Reclast Prescribing Information. Novartis Pharmaceuticals Corp; 2015.Google Scholar
  23. 23.
    Lyles KW, Colón-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007;357:1799–809.CrossRefGoogle Scholar
  24. 24.
    Beaupre LA, Morrish DW, Hanley DA, et al. Oral bisphosphonates are associated with reduced mortality after hip fracture. Osteoporos Int. 2011;22:983–91.CrossRefGoogle Scholar
  25. 25.
    Miller PD, Jamal SA, Evenepoel P, Eastell R, Boonen S. Renal safety in patients treated with bisphosphonates for osteoporosis: a review. J Bone Miner Res. 2013;28:2049–59.CrossRefGoogle Scholar
  26. 26.
    Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. JAMA. 1999;281:2189–97.CrossRefGoogle Scholar
  27. 27.
    Evista Prescribing Information. Eli Lilly and Company; 2011.Google Scholar
  28. 28.
    Conbriza Prescribing Information [EMA]. Pfizer Limited; 2014.Google Scholar
  29. 29.
    Barrett-Connor E, Grady D, Sashegyi A, et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE randomized trial. JAMA. 2002;287:847–57.CrossRefGoogle Scholar
  30. 30.
    McClung MR, Lewiecki EM, Cohen SB, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med. 2006;354:821–31.CrossRefGoogle Scholar
  31. 31.
    Bone HG, Wagman RB, Brandi ML, et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 2017;5:513–23.CrossRefGoogle Scholar
  32. 32.
    Kendler DL, Roux C, Benhamou CL, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res. 2010;25:72–81.CrossRefGoogle Scholar
  33. 33.
    Prolia Prescribing Information. Amgen Inc; 2017.Google Scholar
  34. 34.
    Jamal SA, Ljunggren O, Stehman-Breen C, et al. Effects of denosumab on fracture and bone mineral density by level of kidney function. J Bone Miner Res. 2011;26:1829–35.CrossRefGoogle Scholar
  35. 35.
    Miller PD, Bolognese MA, Lewiecki EM, et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone. 2008;43:222–9.CrossRefGoogle Scholar
  36. 36.
    Cummings SR, Ferrari S, Eastell R, et al. Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension. J Bone Miner Res. 2018;33:190–8.CrossRefGoogle Scholar
  37. 37.
    Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344:1434–41.CrossRefGoogle Scholar
  38. 38.
    Keaveny TM, McClung MR, Wan X, Kopperdahl DL, Mitlak BH, Krohn K. Femoral strength in osteoporotic women treated with teriparatide or alendronate. Bone. 2012;50:165–70.CrossRefGoogle Scholar
  39. 39.
    Forteo Prescribing Information. Eli Lilly and Company; 2012.Google Scholar
  40. 40.
    Kendler DL, Marin F, CAF Z, et al. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet. 2017.; pii: S0140-6736(17)32137-2Google Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Oregon Osteoporosis CenterPortlandUSA

Personalised recommendations